Skip to main content
Erschienen in: Clinical Journal of Gastroenterology 2/2015

01.04.2015 | Clinical Review

Gastrointestinal bleeding with continuous-flow left ventricular assist devices

verfasst von: Syed Amer, Parth Shah, Syed Hassan

Erschienen in: Clinical Journal of Gastroenterology | Ausgabe 2/2015

Einloggen, um Zugang zu erhalten

Abstract

Continuous-flow left ventricular assist device (CF-LVAD) insertion is a life-saving procedure that is being increasingly used in patients with advanced heart failure. However, patients with CF-LVADs are at an increased risk of gastrointestinal bleeding (GIB). Bleeding can occur anywhere in the GI tract with lesions being more prevalent in the upper GI tract than in the lower GI tract. The pathophysiology of GIB in patients with CF-LVADs is unique and likely involves three synergistic mechanisms—coagulopathy, acquired von Willebrand disease and continuous non-pulsatile blood flow. Management strategies vary depending on the presentation and site of bleeding. Prevention strategies to prevent GIB in these patients include low pump speed, close hemodynamic monitoring and a low threshold for endoscopy. We aim to review in detail the pathophysiology, management, complications and preventive strategies in patients with CF-LVAD who present with GIB.
Literatur
1.
Zurück zum Zitat Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics—2013 update: a report from the American heart association. Circulation. 2013;127:e6–245.CrossRefPubMed Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics—2013 update: a report from the American heart association. Circulation. 2013;127:e6–245.CrossRefPubMed
2.
Zurück zum Zitat Miller LW, Pagani FD, Russell SD, et al. HeartMate II Clinical Investigators. Frazier OH use of a continuous-flow device in patients awaiting heart transplantation. N Engl J Med. 2007;357:885–96.CrossRefPubMed Miller LW, Pagani FD, Russell SD, et al. HeartMate II Clinical Investigators. Frazier OH use of a continuous-flow device in patients awaiting heart transplantation. N Engl J Med. 2007;357:885–96.CrossRefPubMed
3.
Zurück zum Zitat Slaughter MS, Rogers JG, Milano CA, et al. Advanced heart failure treated with continuous-flow left ventricular assist device. N Engl J Med. 2009;361:2241–51.CrossRefPubMed Slaughter MS, Rogers JG, Milano CA, et al. Advanced heart failure treated with continuous-flow left ventricular assist device. N Engl J Med. 2009;361:2241–51.CrossRefPubMed
4.
Zurück zum Zitat Rose EA, Gelijns AC, Moskowitz AJ, et al. Long-term use of a left ventricular assist device for end-stage heart failure. N Engl J Med. 2001;345:1435–43.CrossRefPubMed Rose EA, Gelijns AC, Moskowitz AJ, et al. Long-term use of a left ventricular assist device for end-stage heart failure. N Engl J Med. 2001;345:1435–43.CrossRefPubMed
5.
Zurück zum Zitat John R, Kamdar F, Liao K, et al. Low thromboembolic risk for patients with the Heartmate II left ventricular assist device. J Thorac Cardiovasc Surg. 2008;136:1318–23.CrossRefPubMed John R, Kamdar F, Liao K, et al. Low thromboembolic risk for patients with the Heartmate II left ventricular assist device. J Thorac Cardiovasc Surg. 2008;136:1318–23.CrossRefPubMed
6.
Zurück zum Zitat Holman WL, Rayburn BK, McGiffin DC, et al. Infection in ventricular assist devices: prevention and treatment. Ann Thorac Surg. 2003;75(suppl):S48–57.CrossRefPubMed Holman WL, Rayburn BK, McGiffin DC, et al. Infection in ventricular assist devices: prevention and treatment. Ann Thorac Surg. 2003;75(suppl):S48–57.CrossRefPubMed
8.
Zurück zum Zitat Miller LW, Pagani FD, Russell SD, et al. Use of a continuous-flow device in patients awaiting heart transplantation. N Engl J Med. 2007;357:885–96.CrossRefPubMed Miller LW, Pagani FD, Russell SD, et al. Use of a continuous-flow device in patients awaiting heart transplantation. N Engl J Med. 2007;357:885–96.CrossRefPubMed
9.
Zurück zum Zitat Kamdar F, Boyle A, Liao K, et al. Effects of centrifugal, axial and pulsatile left ventricular assist device support on end organ function in heart failure patients. J Heart Lung Transplant. 2009;28:352–9.CrossRefPubMed Kamdar F, Boyle A, Liao K, et al. Effects of centrifugal, axial and pulsatile left ventricular assist device support on end organ function in heart failure patients. J Heart Lung Transplant. 2009;28:352–9.CrossRefPubMed
10.
Zurück zum Zitat Uriel N, Pak SW, Jorde UP, et al. Acquired von Willebrand syndrome after continuous-flow mechanical device support contributes to a high prevalence of bleeding during long-term support and at the time of transplantation. J Am Coll Cardiol. 2010;56:1207–13.CrossRefPubMed Uriel N, Pak SW, Jorde UP, et al. Acquired von Willebrand syndrome after continuous-flow mechanical device support contributes to a high prevalence of bleeding during long-term support and at the time of transplantation. J Am Coll Cardiol. 2010;56:1207–13.CrossRefPubMed
11.
Zurück zum Zitat Morgan JA, Paone G, Nemeh HW, et al. Gastrointestinal bleeding with the HeartMate II left ventricular assist device. J Heart Lung Transplant. 2012;31:715–8.CrossRefPubMed Morgan JA, Paone G, Nemeh HW, et al. Gastrointestinal bleeding with the HeartMate II left ventricular assist device. J Heart Lung Transplant. 2012;31:715–8.CrossRefPubMed
12.
Zurück zum Zitat John R. Lessons learned from experience with over 100 consecutive HeartMate II leftventricular assist devices. Ann Thorac Surg. 2011;92:1593–9.CrossRefPubMed John R. Lessons learned from experience with over 100 consecutive HeartMate II leftventricular assist devices. Ann Thorac Surg. 2011;92:1593–9.CrossRefPubMed
13.
Zurück zum Zitat Stern DR, Kazam J, Edwards P, et al. Increased incidence of gastrointestinal bleeding following implantation of the HeartMate II LVAD. J Card Surg. 2010;25:352–6.CrossRefPubMed Stern DR, Kazam J, Edwards P, et al. Increased incidence of gastrointestinal bleeding following implantation of the HeartMate II LVAD. J Card Surg. 2010;25:352–6.CrossRefPubMed
14.
Zurück zum Zitat Daas AY, Small MB, Pinkas H, et al. Safety of conventional and wireless capsule endoscopy in patients supported with nonpulsatile axial flow heart-mate II left ventricular assist device. Gastrointest Endosc. 2008;68:379–82.CrossRefPubMed Daas AY, Small MB, Pinkas H, et al. Safety of conventional and wireless capsule endoscopy in patients supported with nonpulsatile axial flow heart-mate II left ventricular assist device. Gastrointest Endosc. 2008;68:379–82.CrossRefPubMed
15.
Zurück zum Zitat Letsou GV, Shah N, Gregoric ID, et al. Gastrointestinal bleeding from arteriovenous malformations in patients supported by the Jarvik 2000 axial-flow left ventricular assist device. J Heart Lung Transplant. 2005;24:105–9.CrossRefPubMed Letsou GV, Shah N, Gregoric ID, et al. Gastrointestinal bleeding from arteriovenous malformations in patients supported by the Jarvik 2000 axial-flow left ventricular assist device. J Heart Lung Transplant. 2005;24:105–9.CrossRefPubMed
16.
Zurück zum Zitat Islam S, Cevik C, Madonna R, et al. Left ventricular assist devices and gastrointestinal bleeding: a narrative review of case reports and case series. Clin Cardiol. 2013;36:190–200.CrossRefPubMed Islam S, Cevik C, Madonna R, et al. Left ventricular assist devices and gastrointestinal bleeding: a narrative review of case reports and case series. Clin Cardiol. 2013;36:190–200.CrossRefPubMed
17.
Zurück zum Zitat Aggarwal A, Pant R, Kumar S, et al. Incidence and management of gastrointestinal bleeding with continuous flow assist devices. Ann Thorac Surg. 2012;93:1534–40.CrossRefPubMed Aggarwal A, Pant R, Kumar S, et al. Incidence and management of gastrointestinal bleeding with continuous flow assist devices. Ann Thorac Surg. 2012;93:1534–40.CrossRefPubMed
18.
Zurück zum Zitat Crow S, John R, Boyle A, et al. Gastrointestinal bleeding rates in recipients of nonpulsatile and pulsatile left ventricular assist devices. J Thorac Cardiovasc Surg. 2009;137:208–15.CrossRefPubMed Crow S, John R, Boyle A, et al. Gastrointestinal bleeding rates in recipients of nonpulsatile and pulsatile left ventricular assist devices. J Thorac Cardiovasc Surg. 2009;137:208–15.CrossRefPubMed
19.
Zurück zum Zitat Heyde E. Gastrointestinal bleeding in aortic stenosis. N Engl J Med. 1958;259:196–200. Heyde E. Gastrointestinal bleeding in aortic stenosis. N Engl J Med. 1958;259:196–200.
20.
Zurück zum Zitat Warkentin TE, Moore JC, Morgan DG. Aortic stenosis and bleeding gastrointestinal angiodysplasia: is acquired von Willebrand’s disease the link? Lancet. 1992;340:35–7.CrossRefPubMed Warkentin TE, Moore JC, Morgan DG. Aortic stenosis and bleeding gastrointestinal angiodysplasia: is acquired von Willebrand’s disease the link? Lancet. 1992;340:35–7.CrossRefPubMed
21.
Zurück zum Zitat Federici AB, Rand JH, Bucciarelli P. Acquired von Willebrand syndrome: data from an international registry. Thromb Haemost. 2000;84:345–9.PubMed Federici AB, Rand JH, Bucciarelli P. Acquired von Willebrand syndrome: data from an international registry. Thromb Haemost. 2000;84:345–9.PubMed
22.
Zurück zum Zitat Tsai HM, Sussman II, Nagel RL. Shear stress enhances the proteolysis of von Willebrand factor in normal plasma. Blood. 1994;83:2171–9.PubMed Tsai HM, Sussman II, Nagel RL. Shear stress enhances the proteolysis of von Willebrand factor in normal plasma. Blood. 1994;83:2171–9.PubMed
23.
Zurück zum Zitat Siedlecki CA, Lestini BJ, Kottke-Marchant KK, et al. Shear-dependent changes in the three-dimensional structure of human von Willebrand factor. Blood. 1996;88:2939–50.PubMed Siedlecki CA, Lestini BJ, Kottke-Marchant KK, et al. Shear-dependent changes in the three-dimensional structure of human von Willebrand factor. Blood. 1996;88:2939–50.PubMed
24.
Zurück zum Zitat Vincentelli A, Susen S, Le Tourneau T. Acquired von Willebrand syndrome in aortic stenosis. N Engl J Med. 2003;349:343–9.CrossRefPubMed Vincentelli A, Susen S, Le Tourneau T. Acquired von Willebrand syndrome in aortic stenosis. N Engl J Med. 2003;349:343–9.CrossRefPubMed
25.
Zurück zum Zitat Demirozu ZT, Radovancevic R, Hochman LF, et al. Arteriovenous malformation and gastrointestinal bleeding in patients with the Heart-Mate II left ventricular assist device. J Heart Lung Transplant. 2011;30:849–53.CrossRefPubMed Demirozu ZT, Radovancevic R, Hochman LF, et al. Arteriovenous malformation and gastrointestinal bleeding in patients with the Heart-Mate II left ventricular assist device. J Heart Lung Transplant. 2011;30:849–53.CrossRefPubMed
26.
Zurück zum Zitat Hayes HM, Dembo LG, Larbalestier R, et al. Management options to treat gastrointestinal bleeding in patients supported on rotary left ventricular assist devices: a single-center experience. Artif Organs. 2010;34:703–6.CrossRefPubMed Hayes HM, Dembo LG, Larbalestier R, et al. Management options to treat gastrointestinal bleeding in patients supported on rotary left ventricular assist devices: a single-center experience. Artif Organs. 2010;34:703–6.CrossRefPubMed
27.
Zurück zum Zitat Lamberts SW, van der Lely AJ, de Herder WW, Hofland LJ. Octreotide. N Eng J Med. 1996;334:246–54.CrossRef Lamberts SW, van der Lely AJ, de Herder WW, Hofland LJ. Octreotide. N Eng J Med. 1996;334:246–54.CrossRef
28.
Zurück zum Zitat Kurosaki M, Saegert W, Abe T, et al. Expression of vascular endothelial growth factor in growth hormone-secreting pituitary adenomas: special reference to the octreotide treatment. Neurol Res. 2008;30:518–22.CrossRefPubMed Kurosaki M, Saegert W, Abe T, et al. Expression of vascular endothelial growth factor in growth hormone-secreting pituitary adenomas: special reference to the octreotide treatment. Neurol Res. 2008;30:518–22.CrossRefPubMed
29.
Zurück zum Zitat Rennyson SL, Shah KB, Tang DG, et al. Octreotide for left ventricular assist device-related gastrointestinal hemorrhage: can we stop the bleeding? ASAIO J. 2013;59:450–1.CrossRefPubMed Rennyson SL, Shah KB, Tang DG, et al. Octreotide for left ventricular assist device-related gastrointestinal hemorrhage: can we stop the bleeding? ASAIO J. 2013;59:450–1.CrossRefPubMed
30.
Zurück zum Zitat Ge ZZ, Chen HM, Gao YJ, et al. Efficacy of thalidomide for refractory gastrointestinal bleeding from vascular malformation. Gastroenterology. 2011;141(1629–37):e1–4.PubMed Ge ZZ, Chen HM, Gao YJ, et al. Efficacy of thalidomide for refractory gastrointestinal bleeding from vascular malformation. Gastroenterology. 2011;141(1629–37):e1–4.PubMed
31.
Zurück zum Zitat Garrido A, Sayago M, Lopez J, et al. Thalidomide in refractory bleeding due to gastrointestinal angiodysplasias. Rev Esp Enferm Dig. 2012;104:69–71.CrossRefPubMed Garrido A, Sayago M, Lopez J, et al. Thalidomide in refractory bleeding due to gastrointestinal angiodysplasias. Rev Esp Enferm Dig. 2012;104:69–71.CrossRefPubMed
32.
Zurück zum Zitat Cushing M. Factor VIII/von Willebrand factor concentrate therapy for ventricular-assist device associated acquired von Willebrand Disease. Transfusion. 2012;52:1535–41.CrossRefPubMed Cushing M. Factor VIII/von Willebrand factor concentrate therapy for ventricular-assist device associated acquired von Willebrand Disease. Transfusion. 2012;52:1535–41.CrossRefPubMed
33.
Zurück zum Zitat Patlolla V, Patten RD, Denofrio D, et al. The effect of ventricular assist devices on post-transplant mortality an analysis of the united network for organ sharing thoracic registry. J Am Coll Cardiol. 2009;53:264–71.CrossRefPubMed Patlolla V, Patten RD, Denofrio D, et al. The effect of ventricular assist devices on post-transplant mortality an analysis of the united network for organ sharing thoracic registry. J Am Coll Cardiol. 2009;53:264–71.CrossRefPubMed
Metadaten
Titel
Gastrointestinal bleeding with continuous-flow left ventricular assist devices
verfasst von
Syed Amer
Parth Shah
Syed Hassan
Publikationsdatum
01.04.2015
Verlag
Springer Japan
Erschienen in
Clinical Journal of Gastroenterology / Ausgabe 2/2015
Print ISSN: 1865-7257
Elektronische ISSN: 1865-7265
DOI
https://doi.org/10.1007/s12328-015-0551-5

Weitere Artikel der Ausgabe 2/2015

Clinical Journal of Gastroenterology 2/2015 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Battle of Experts: Sport vs. Spritze bei Adipositas und Typ-2-Diabetes

11.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Im Battle of Experts traten zwei Experten auf dem Diabeteskongress gegeneinander an: Die eine vertrat die Auffassung „Sport statt Spritze“ bei Adipositas und Typ-2-Diabetes, der andere forderte „Spritze statt Sport!“ Am Ende waren sie sich aber einig: Die Kombination aus beidem erzielt die besten Ergebnisse.

Vorsicht, erhöhte Blutungsgefahr nach PCI!

10.05.2024 Koronare Herzerkrankung Nachrichten

Nach PCI besteht ein erhöhtes Blutungsrisiko, wenn die Behandelten eine verminderte linksventrikuläre Ejektionsfraktion aufweisen. Das Risiko ist umso höher, je stärker die Pumpfunktion eingeschränkt ist.

Triglyzeridsenker schützt nicht nur Hochrisikopatienten

10.05.2024 Hypercholesterinämie Nachrichten

Patienten mit Arteriosklerose-bedingten kardiovaskulären Erkrankungen, die trotz Statineinnahme zu hohe Triglyzeridspiegel haben, profitieren von einer Behandlung mit Icosapent-Ethyl, und zwar unabhängig vom individuellen Risikoprofil.

Gibt es eine Wende bei den bioresorbierbaren Gefäßstützen?

In den USA ist erstmals eine bioresorbierbare Gefäßstütze – auch Scaffold genannt – zur Rekanalisation infrapoplitealer Arterien bei schwerer PAVK zugelassen worden. Das markiert einen Wendepunkt in der Geschichte dieser speziellen Gefäßstützen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.